Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G for Syndax Pharmaceuticals Inc Common Stock (SNDX).
- Disclosed ownership: 6.3%.
- Date of event: 31 Dec 2024.
MORGAN STANLEY - 31 Dec 2024 SCHEDULE 13G Report for Syndax Pharmaceuticals Inc Common Stock (SNDX)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Symbol
- SNDX
- Shares outstanding
- 85,113,794 shares
- Disclosed Ownership
- 5,362,169 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13G
- Filing time
- 05 Feb 2025, 10:03:40 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 07 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 6.3% ownership in Syndax Pharmaceuticals Inc Common Stock (SNDX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 05 Feb 2025, 10:03.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 6.3% | 5,362,169 | 0 | 5,312,117 | Christopher O'Hara | Authorized Signatory, Morgan Stanley | |
| Morgan Stanley & Co. LLC | 5.9% | 5,055,451 | 0 | 5,055,451 | Christopher O'Hara | Authorized Signatory, Morgan Stanley & Co. LLC |